Research map: Physiologically Based Pharmacokinetic Modeling of Vedolizumab in Healthy Adults and Patients with Inflammatory Bowel Disease

Back to the article

Papers in this map

  1. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis · Brian G. Feagan · 2013 · 2918 citations · Cited by this paper
  2. Population Pharmacokinetics of Bosutinib in Children with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Based on a Phase I Dose-Finding Trial (ITCC-054/COG AAML1921) and Pediatric Recommended Phase II Dosage Evaluation · 2026 · Related
  3. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease · William J. Sandborn · 2013 · 2734 citations · Cited by this paper
  4. Quantitative Pharmacology Justifying Ribociclib Dose in Early Breast Cancer · 2026 · Related
  5. Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunities · Stephen B. Hanauer · 2005 · 973 citations · Cited by this paper
  6. Development and Clinical Application of a Real-World Population Pharmacokinetic Model of Rivaroxaban in Asian Patients with Atrial Fibrillation · 2026 · Related
  7. The safety of vedolizumab for ulcerative colitis and Crohn's disease · Jean‐Frédéric Colombel · 2016 · 816 citations · Cited by this paper
  8. Therapeutic Drug Monitoring of Imatinib in Paediatric Chronic Myeloid Leukaemia: Towards Practical Implementation and Interpretation of Measured Plasma Concentrations · 2026 · Related
  9. Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn’s Disease · Elana A. Maser · 2006 · 616 citations · Cited by this paper
  10. A Review of Population Pharmacokinetic Models and Dosing Algorithms Assessing the Influence of CYP3A5 Genotype and Other Clinical Covariates on Tacrolimus Pharmacokinetics · 2026 · Related
  11. The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases · Dulce F. Soler · 2009 · 470 citations · Cited by this paper
  12. Single Saliva Sample Linezolid Dosing for Multidrug-Resistant Tuberculosis: A Population Pharmacokinetic Modelling of Plasma and Saliva · 2026 · Related
  13. Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model · Lars Kuepfer · 2016 · 424 citations · Cited by this paper
  14. Revisited Pharmacokinetic Profiles of Methylprednisolone in Plasma and Urine After Single and Multiple Oral Administrations: Relevance in Sports Drug Testing · 2026 · Related
  15. Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis · Omoniyi J. Adedokun · 2014 · 341 citations · Cited by this paper
  16. Impacts of Uremic Toxins on the Population Pharmacokinetics of Total Mycophenolic Acid and its Glucuronide Metabolite in Adult Kidney Transplant Recipients · 2026 · Related
  17. An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab · Timothy L. Wyant · 2016 · 285 citations · Cited by this paper
  18. Population Pharmacokinetics for Pediatric Extrapolation of GenSci006: A 3.75-mg Triptorelin Acetate Microsphere Formulation for Central Precocious Puberty · 2026 · Related
  19. Approximations of the target-mediated drug disposition model and identifiability of model parameters · Leonid V. Gibiansky · 2008 · 275 citations · Cited by this paper
  20. ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma · 2026 · Related
  21. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease · Maria Rosario · 2015 · 268 citations · Cited by this paper
  22. Quasi-Equilibrium Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition · Donald E. Mager · 2005 · 231 citations · Cited by this paper
  23. Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study · Asit Parikh · 2011 · 212 citations · Cited by this paper
  24. Emerging treatments for inflammatory bowel disease · Karl Hazel · 2020 · 184 citations · Cited by this paper
  25. A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab · Maria Rosario · 2017 · 158 citations · Cited by this paper
  26. Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases · Erwin Dreesen · 2018 · 158 citations · Cited by this paper
  27. Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease · Jean‐Frédéric Colombel · 2011 · 123 citations · Cited by this paper
  28. Dose Selection Based on Physiologically Based Pharmacokinetic (PBPK) Approaches · Hannah M. Jones · 2012 · 107 citations · Cited by this paper
  29. Altered expression of alpha 4 beta 7, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation. · John K. Meenan · 1997 · 106 citations · Cited by this paper
  30. Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation · Mark T. Osterman · 2019 · 89 citations · Cited by this paper
  31. Vedolizumab for the Treatment of Ulcerative Colitis and Crohn‘s Disease · Leon P. McLean · 2012 · 88 citations · Cited by this paper
  32. Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases · Matthew Luzentales-Simpson · 2021 · 85 citations · Cited by this paper
  33. Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last · Catherine Le Berre · 2022 · 78 citations · Cited by this paper
  34. Advancements in Inflammatory Bowel Disease: A Narrative Review of Diagnostics, Management, Epidemiology, Prevalence, Patient Outcomes, Quality of Life, and Clinical Presentation · Muhammad Ali Muzammil · 2023 · 74 citations · Cited by this paper
  35. Systematic review with meta‐analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases · Siddharth Singh · 2019 · 69 citations · Cited by this paper
  36. Anin vitroFcRn- dependent transcytosis assay as a screening tool for predictive assessment of nonspecific clearance of antibody therapeutics in humans · Shan Chung · 2019 · 65 citations · Cited by this paper
  37. Simulation of Monoclonal Antibody Pharmacokinetics in HumansUsing a Minimal Physiologically Based Model · Linzhong Li · 2014 · 62 citations · Cited by this paper
  38. Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases · Timo Räth · 2018 · 60 citations · Cited by this paper
  39. A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study · Marco Vincenzo Lenti · 2018 · 58 citations · Cited by this paper

Source: OpenAlex (CC0)